Wire · opportunities
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 August 2026 · Fusion42 review
Acurx Pharmaceuticals has received FDA conditional acceptance and USPTO trademark allowance for the brand name CIFBEZY for its lead antibiotic candidate ibezapolstat aimed at treating and reducing recurrence of Clostridioides difficile infection (CDI). The company is preparing to advance ibezapolstat into international Phase 3 clinical trials, with FDA guidance supporting potential NDA filing based on a single Phase 3 trial.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now prepare for commercial branding and capitalise on FDA and USPTO milestones to set a foothold in the CDI treatment market before Phase 3 completion. Competitors will lag on brand establishment while you build recognition ahead of approval.
◆ Coverage
1 source · 17 Aug 2026
◆ Related on Wire
◆ Topics